After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical stocks in early February. The largest upswings happened to BioMarin Pharmaceutical and Amgen.
ThinkstockThe initial public offering market has been rather strong in 2014. After we recently featured our Top 10 IPOs to Watch in 2014, we took a look at the batch of the many IPOs…
Shares of biotechnology company Anika Therapeutics soared to an all-time high Wednesday after the company said the FDA had approved its drug to treat pain and improve joint mobility in patients with osteoarthritis of…
ThinkstockVIVUS Inc. (NASDAQ: VVUS) is suffering from what looked like good news on the surface. The reality, and the catch about investing, is that things can often be much more complicated than an earnings…
ThinkstockShares of biotech company InterMune Inc. (NASDAQ: ITMN) more than doubled Tuesday after the company said its experimental drug pirfenidone, in a late-stage trial, reduced the progression of a disease that leads to loss…
ThinkstockThe biotech market has been on fire this year, and there is every indication that things will continue. With huge binary events right around the corner, and many of the top companies with clinical…
Shares of Emeritus and Brookdale Senior Living were rising nicely Friday as investors cheered the merger of the big assisted-living companies and bet that more deals are ahead.
Chelsea Therapeutics is finding a serious victory from its hypotension drug. Shares hit a multiyear high after it confirmed an accelerated FDA approval of its Northera for the treatment of low blood pressure.
Biogen Idec has announced that Chairman William D. Young will retire from the its board of directors and will be replaced by Stelios Papadopoulos. The latter is a former investment banker specializing in life-sciences…
Novartis announced Monday morning that it will acquire privately held startup biotech CoStim Pharmaceuticals. Terms of the deal were not revealed, but it will bolster Novartis's cancer immunotherapy portfolio.
With top biotechnology and health care companies from around the world attending the Leerink Global Healthcare, it is a good chance for investors to get timely updates on the top stocks and their prospects…
24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January.
ThinkstockHealth insurance providers are not having a good start to 2014. The Affordable Care Act, or Obamacare, is not bringing in enough young subscribers to offset the costs of those who are in their…
Cadence Pharmaceuticals agreed Tuesday to be bought out by Mallinckrodt for $1.3 billion, or a more than 27% premium to Monday's closing share price. Some investors may anticipate a sweetened offer.
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is rising on Monday after two analysts made positive calls on the biotech giant. As a reminder, Gilead is now the world’s largest pure-play biotech as the market cap…